Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Caffeine 200 mg Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers

NCT01766050
View directory record Official record
Conditions
Transplant Rejection
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Belatacept
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Different Dosages of Paraxanthine, the Major Caffeine Metabolite, on Energy and Focus

NCT06117280
View directory record Official record
Conditions
Energy, Focus, Caffeine Withdrawal
Interventions
Paraxanthine 200 mg, Paraxanthine 300 mg, Placebo
Other
Lead sponsor
Iovate Health Sciences International Inc
Industry
Eligibility
18 Years to 35 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Not applicable Interventional

Treatment of Low Metabolic Rate Following Bariatric Surgery

NCT01596907
View directory record Official record
Conditions
Morbid Obesity
Interventions
Ephedrine sulfate with caffeine, cellulose
Drug
Lead sponsor
Oregon Weight Loss Surgery, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Beaverton, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 2, 2026, 6:50 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Caffeine Consumption in Glaucoma Patients and Healthy Subjects

NCT03675412
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
Caffeine tablet
Dietary Supplement
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Results available

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

NCT02688088
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
Drug Cocktail, Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Denver, Colorado • Indianapolis, Indiana • Fairway, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 3 Interventional Results available

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

NCT00826280
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
regadenoson, overencapsulated caffeine, technetium, placebo
Drug · Radiation
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • La Mesa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 2, 2026, 6:50 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache

NCT01842633
View directory record Official record
Conditions
Pain
Interventions
Paracetamol and Caffeine, Ibuprofen, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

NCT05657613
View directory record Official record
Conditions
Drug Interactions
Interventions
CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin

NCT02685462
View directory record Official record
Conditions
Healthy
Interventions
Rosuvastatin, Atorvastatin, Simvastatin, Digoxin, Caffeine
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 3 Interventional Results available

Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)

NCT00809471
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
placebo, avanafil
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect and CYP1A2 Induction Study in Healthy Subjects

NCT02168205
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Pomalidomide, Caffeine, Tobacco
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
40 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Not applicable Interventional Results available

Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD

NCT00363298
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
dextro-amphetamine, Sham Comparison
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants

NCT04655040
View directory record Official record
Conditions
Healthy Participants
Interventions
Caffeine, Ritlecitinib
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise-Induced Rates of Fat Oxidation with and Without Ingestion of a Caffeine-Based Energy Drink

NCT06308731
View directory record Official record
Conditions
Substrate Oxidation, Energy Expenditure, Reaction Time, Cognition, Exercise Performance
Interventions
Caffeine-Based Energy Drink, Placebo
Dietary Supplement · Other
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants

NCT05067439
View directory record Official record
Conditions
Healthy Participants
Interventions
Abrocitinib, Omeprazole, Caffeine, Efavirenz
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants

NCT06215430
View directory record Official record
Conditions
Healthy
Interventions
Caffeine Tablet, Omeprazole capsule, Warfarin tablet, Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized Study to Examine the Ability of a Caffeine-Based Energy Drink to Impact Energy Expenditure, Fat Oxidation, Reaction Time, and Other Perceptual Indicators

NCT05998096
View directory record Official record
Conditions
Energy Expenditure, Cognition, Reaction Time
Interventions
Caffeine-Based Energy Drink, Placebo
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults

NCT04425902
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254 200 mg, Caffeine 200 mg, Metoprolol 100 mg, Montelukast 10 mg, Flurbiprofen 100 mg, Omeprazole 40 mg, Midazolam 5 mg (2.5 mL), Digoxin 0.25 mg, Pravastatin 40 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 2, 2026, 6:50 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

NCT04764851
View directory record Official record
Conditions
Drug-Interactions
Interventions
ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail, Cohort 3 Probe Cocktail
Drug · Combination Product
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue

NCT01944215
View directory record Official record
Conditions
Molecular Imaging
Interventions
Meal, Exercise, Sestamibi, Caffeine Tablet, External Heating
Dietary Supplement · Other · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 2, 2026, 6:50 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

NCT02760615
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn Disease
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 1 Interventional

A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes

NCT00401583
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
GW786034 (pazopanib), Probe drugs
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 1 Interventional

Treatment of Orthostatic Hypotension in Autonomic Failure

NCT00223691
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Not applicable Interventional

Does Caffeine Affect the Sensitivity of Adenosine Perfusion Scans?

NCT00205166
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Cardiac SPECT imaging Rest and Stress, Caffeine
Procedure · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 28, 2012 · Synced Sep 2, 2026, 6:50 PM EDT